10,000 Shares in Liquidia Co. (NASDAQ:LQDA) Acquired by Clear Harbor Asset Management LLC

Clear Harbor Asset Management LLC acquired a new stake in Liquidia Co. (NASDAQ:LQDA) in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 10,000 shares of the company’s stock, valued at approximately $100,000.

A number of other hedge funds also recently made changes to their positions in the company. Quest Partners LLC acquired a new stake in Liquidia during the 2nd quarter valued at approximately $27,000. Hilltop National Bank acquired a new stake in shares of Liquidia during the second quarter worth approximately $33,000. Signaturefd LLC increased its stake in shares of Liquidia by 38,400.0% in the third quarter. Signaturefd LLC now owns 10,010 shares of the company’s stock worth $100,000 after buying an additional 9,984 shares during the last quarter. Ballentine Partners LLC acquired a new stake in Liquidia in the third quarter valued at $110,000. Finally, Whitcomb & Hess Inc. boosted its stake in Liquidia by 10.2% during the 3rd quarter. Whitcomb & Hess Inc. now owns 11,599 shares of the company’s stock valued at $116,000 after acquiring an additional 1,074 shares during the last quarter. Hedge funds and other institutional investors own 64.54% of the company’s stock.

Insider Buying and Selling

In other news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction on Monday, October 14th. The stock was sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the transaction, the chief executive officer now owns 812,193 shares of the company’s stock, valued at approximately $9,023,464.23. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, CEO Roger Jeffs sold 8,053 shares of the stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $11.11, for a total value of $89,468.83. Following the completion of the transaction, the chief executive officer now directly owns 812,193 shares in the company, valued at $9,023,464.23. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Rajeev Saggar sold 2,526 shares of the firm’s stock in a transaction that occurred on Friday, October 18th. The shares were sold at an average price of $11.19, for a total transaction of $28,265.94. Following the transaction, the insider now owns 204,857 shares in the company, valued at $2,292,349.83. This represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 21,551 shares of company stock valued at $236,021 in the last three months. 30.10% of the stock is currently owned by corporate insiders.

Liquidia Stock Performance

Shares of LQDA opened at $11.01 on Monday. The firm has a fifty day moving average of $10.18 and a 200-day moving average of $11.75. The company has a market cap of $845.46 million, a price-to-earnings ratio of -7.01 and a beta of 0.22. Liquidia Co. has a 1 year low of $6.06 and a 1 year high of $16.99.

Liquidia (NASDAQ:LQDA) last posted its earnings results on Wednesday, August 7th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). Liquidia had a negative return on equity of 183.57% and a negative net margin of 755.46%. The firm had revenue of $3.66 million during the quarter, compared to the consensus estimate of $7.92 million. Analysts predict that Liquidia Co. will post -1.69 EPS for the current year.

Wall Street Analyst Weigh In

Several research firms have recently weighed in on LQDA. Lifesci Capital initiated coverage on shares of Liquidia in a research report on Thursday, October 3rd. They issued an “outperform” rating and a $30.00 target price for the company. Bank of America cut their price objective on Liquidia from $24.00 to $23.00 and set a “buy” rating on the stock in a research note on Tuesday, August 20th. Needham & Company LLC reiterated a “buy” rating and issued a $25.00 target price on shares of Liquidia in a research report on Monday, August 19th. HC Wainwright dropped their price target on Liquidia from $32.00 to $29.00 and set a “buy” rating on the stock in a research report on Tuesday, August 20th. Finally, BTIG Research decreased their price objective on shares of Liquidia from $29.00 to $25.00 and set a “buy” rating for the company in a report on Monday, August 19th. One analyst has rated the stock with a sell rating, one has issued a hold rating, six have given a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Liquidia has a consensus rating of “Moderate Buy” and an average target price of $24.67.

Liquidia Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).